This study developed a signature featuring 8 OARGs (HLA-B, RBBP8, SPRY4, WT1, WWOX, UPRT, PELO, ZNF208) and determined its prognostic and functional implications in breast cancer patients. This evidence concerns the gene PELO and breast cancer.